Lactulose and Glucose Breath Tests as Predictors of Clinical Benefit From Rifaximin in Irritable Bowel Syndrome
NCT01803724
·
clinicaltrials.gov ↗
UNKNOWN
Status
120
Enrollment
OTHER
Sponsor class
Conditions
Irritable Bowel Syndrome
Sponsor
Pontificia Universidad Catolica de Chile